"When I started specializing in myeloma two decades ago, median survival was about 2.5 years. Today, we have aggressive and effective therapies available, like our tandem transplant protocol, that have increased median survival to 10 years or more."
Guido Tricot, MD, PhD, is the director of Holden Cancer Center’s Bone Marrow Transplant and Myeloma Program at UI Hospitals and Clinics. He specializes in multiple myeloma and has been researching and treating this type of cancer for over 20 years.
His team’s treatment strategies are based on tandem autologous transplantation, a treatment approach that has increased the median survival rate of patients to 10 years or more.
The long-term outcome data of Dr. Tricot’s treatment methods have appeared in the New England Journal of Medicine, the Lancet, the Journal of Clinical Oncology, Blood, the British Journal of Haematology, and others. He is also a peer reviewer for many medical journals.
He received his medical and doctoral degree at the University of Leuven in Belgium. Before joining Holden Cancer Center, he was director of the Utah Blood and Marrow Transplant and Myeloma Program at Huntsman Cancer Institute.
Prior to that, he was Director of Clinical Research at the University of Arkansas Myeloma Institute for Research and Therapy. He has also served as Director of Bone Marrow and Stem Cell Transplantation at the Greenebaum Cancer Center at the University of Maryland and at Indiana University.